Optimisation of a triazolopyridine based histone demethylase inhibitor yields a potent and selective KDM2A (FBXL11) inhibitor.
Medchemcomm
; 5(12): 1879-1886, 2014 Dec 01.
Article
en En
| MEDLINE
| ID: mdl-26682034
ABSTRACT
A potent inhibitor of the JmjC histone lysine demethylase KDM2A (compound 35, pIC50 7.2) with excellent selectivity over representatives from other KDM subfamilies has been developed; the discovery that a triazolopyridine compound binds to the active site of JmjC KDMs was followed by optimisation of the triazole substituent for KDM2A inhibition and selectivity.
Texto completo:
1
Base de datos:
MEDLINE
Idioma:
En
Revista:
Medchemcomm
Año:
2014
Tipo del documento:
Article